ELIF ORAL, MD
Osteopathic Medicine in Ann Arbor, MI
License number
Michigan 4301062175
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Michigan 4301062175
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
24 Frank Lloyd Wright Dr Lobby C SUITE 1300, Ann Arbor, MI 48105
Phone
(734) 998-2450
(734) 936-2047
(734) 936-2047
Personal information
See more information about ELIF ORAL at radaris.comName
Address
Phone
280 High Orchard Dr, Ann Arbor, MI 48105
Organization information
See more information about ELIF ORAL at bizstanding.comElif Oral MD
400 E Eisenhower Pkwy, Ann Arbor, MI 48108
Industry:
Internist
Phone:
(734) 647-5871 (Phone)
Elif Arioglu Oral
Professional information
Elif Oral, Ann Arbor MI
Specialties:
Internist
Address:
1500 E Medical Center Dr, Ann Arbor, MI 48109
3621 S State St, Ann Arbor, MI 48108
3621 S State St, Ann Arbor, MI 48108
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Endocrinology, Diabetes, and Metabolism (Internal Medicine)
Elif Oral, Ann Arbor MI
Specialties:
Internal Medicine, Endocrinology, Diabetes & Metabolism, Endocrinology and Metabolism
Work:
Va Ann Arbor Healthcare System
2215 Fuller Rd, Ann Arbor, MI 48105 University of Michigan Medical School
1500 E Medical Center Dr, Ann Arbor, MI 48109
2215 Fuller Rd, Ann Arbor, MI 48105 University of Michigan Medical School
1500 E Medical Center Dr, Ann Arbor, MI 48109
Education:
Istanbul Universitesi, Cerrahpasa (1992)
Dr. Elif Oral, Ann Arbor MI - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism
Address:
University Michigan Health END
24 Frank Lloyd Wright Dr, Ann Arbor 48105
(734) 647-5871 (Phone)
24 Frank Lloyd Wright Dr, Ann Arbor 48105
(734) 647-5871 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 2010, Internal Medicine, 1999
Awards:
Healthgrades Honor Roll
Languages:
English, Turkish
Hospitals:
University Michigan Health END
24 Frank Lloyd Wright Dr, Ann Arbor 48105
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
24 Frank Lloyd Wright Dr, Ann Arbor 48105
University of Michigan Health System
1500 East Medical Center Dr SPC 5474, Ann Arbor 48109
Education:
Medical School
Istanbul Universitesi, Cerrahpasa Tip Fakultesi
Graduated: 1992
Clinical Center At The Nih
Sinai Grace Hosp/Sinai Hospital
Istanbul Universitesi, Cerrahpasa Tip Fakultesi
Graduated: 1992
Clinical Center At The Nih
Sinai Grace Hosp/Sinai Hospital
Device And System For Gastric Volume Reduction To Facilitate Weight Loss
US Patent:
2013013, May 23, 2013
Filed:
May 26, 2011
Appl. No.:
13/700368
Inventors:
Elif A. Oral - Ann Arbor MI, US
Hakan Oral - Ann Arbor MI, US
Hakan Oral - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61M 29/02
US Classification:
606192
Abstract:
An ingestible gastric volume reduction device () is provided that is controllably adjustable between an expanded state and a contracted state. A control subsystem within the device is able to selectively transition the device between both states. Such control can be by way of a biological or chemical sensor () in the device, a wireless (RF) receiver (), or timer. Thus activation of the device whether to expand and fill a gastric volume or to contract to open up the gastric volume may be achieved from internal control (within device) or external control (to the device). The device may be used for patient treatment, by administering the device (e.g., through ingestion) to a gastric region and then controllably increasing and/or decreasing the volume of the device during treatment.
Use Of Leptin For Treating Human Lipoatrophy And Method Of Determining Predisposition To Said Treatment
US Patent:
2007009, May 3, 2007
Filed:
Nov 29, 2006
Appl. No.:
11/606805
Inventors:
Alexander DePaoli - Santa Barbara CA, US
Simeon Taylor - Skillman NJ, US
Elif Oral - Ann Arbor MI, US
Abhimanyu Garg - Dallas TX, US
Simeon Taylor - Skillman NJ, US
Elif Oral - Ann Arbor MI, US
Abhimanyu Garg - Dallas TX, US
Assignee:
Amgen, Inc. - Thousand Oaks CA
The Govt. of the U.S.A. as represented by the Secretary, Dept. of Health & Human Services - Rockville MD
Board of Regents, The University of Texas System - Austin TX
The Govt. of the U.S.A. as represented by the Secretary, Dept. of Health & Human Services - Rockville MD
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 38/17
US Classification:
514012000
Abstract:
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
Use Of Leptin For Treating Human Lipoatrophy And Method Of Determining Predisposition To Said Treatment
US Patent:
2013019, Jul 25, 2013
Filed:
Nov 5, 2012
Appl. No.:
13/669324
Inventors:
Alexander M. DePaoli - Santa Barbara CA, US
Elif Ariogiu Oral - Ann Arbor MI, US
Simeon I. Taylor - Skillman NJ, US
Abhimanyu Garg - Dallas TX, US
Elif Ariogiu Oral - Ann Arbor MI, US
Simeon I. Taylor - Skillman NJ, US
Abhimanyu Garg - Dallas TX, US
International Classification:
A61K 38/22, G01N 33/68
US Classification:
514 19, 514 58, 53038824, 5303892, 435 792
Abstract:
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
Use Of Leptin To Treat Metabolic Abnormalities Associated With Lipoatrophy
US Patent:
8318666, Nov 27, 2012
Filed:
May 9, 2011
Appl. No.:
13/103294
Inventors:
Alexander M. DePaoli - Santa Barbara CA, US
Elif Arioglu Oral - Ann Arbor MI, US
Simeon I. Taylor - Skillman NJ, US
Abhimanyu Garg - Dallas TX, US
Elif Arioglu Oral - Ann Arbor MI, US
Simeon I. Taylor - Skillman NJ, US
Abhimanyu Garg - Dallas TX, US
Assignee:
Amgen, Inc. - Thousand Oaks CA
The United States of America, as Represented by the Secretary, Department of Health and Human Services - Washington DC
Board of Regents, The University of Texas System - Austin TX
The United States of America, as Represented by the Secretary, Department of Health and Human Services - Washington DC
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 38/00, A61K 38/22, A61P 3/06
US Classification:
514 58, 514 74
Abstract:
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
Method Of Treating Fatty Liver Diseases And Conditions In Non-Lipodystrophic Subjects
US Patent:
8501686, Aug 6, 2013
Filed:
Jun 5, 2009
Appl. No.:
12/995842
Inventors:
Elif A. Oral - Ann Arbor MI, US
Charles F. Burant - Ann Arbor MI, US
Thomas L. Chenevert - Ann Arbor MI, US
Hero K. Hussain - Ann Arbor MI, US
Barbara J. McKenna - Ann Arbor MI, US
Charles F. Burant - Ann Arbor MI, US
Thomas L. Chenevert - Ann Arbor MI, US
Hero K. Hussain - Ann Arbor MI, US
Barbara J. McKenna - Ann Arbor MI, US
Assignee:
University of Michigan - Ann Arbor MI
International Classification:
A61K 38/22, A61P 3/06
US Classification:
514 58, 530350
Abstract:
The invention generally relates to the use of leptin in the treatment of a leptin-responsive disease or condition in a non-lipodystrophic subject. More particularly, the invention is directed to the use of leptin in the treatment of a fatty liver disease in a non-lipodystrophic subject with a relative leptin deficiency. The invention includes methods for the treatment of nonalcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD) in a non-lipodystrophic subject. The invention includes the treatment of conditions ranging from ectopic lipid accumulation (steatosis) to cirrhosis.
Use Of Leptin For Treating Human Lipoatrophy And Method Of Determining Predisposition To Said Treatment
US Patent:
2005002, Jan 27, 2005
Filed:
Jul 18, 2003
Appl. No.:
10/623189
Inventors:
Alexander DePaoli - Santa Barbara CA, US
Simeon Taylor - Skillman NJ, US
Elif Oral - Ann Arbor MI, US
Abhimanyu Garg - Dallas TX, US
Simeon Taylor - Skillman NJ, US
Elif Oral - Ann Arbor MI, US
Abhimanyu Garg - Dallas TX, US
International Classification:
A61K038/17
US Classification:
514012000
Abstract:
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.